You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Thalidomide and its analogues in the treatment of Multiple Myeloma
|
|---|---|
| Published in |
Experimental Hematology & Oncology, September 2012
|
| DOI | 10.1186/2162-3619-1-27 |
| Pubmed ID | |
| Authors |
Tahir Latif, Nabeel Chauhan, Rashid Khan, Andrea Moran, Saad Z Usmani |
| Abstract |
Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor activity, and have had a positive impact on the natural history of multiple myeloma. Recent advances in the clinical application of these agents and in our understanding of their mechanism of action, and toxicity have made safer and smarter use of these drugs possible. This review discusses the available information regarding mechanisms of action, toxicity and clinical results on thalidomide, lenalidomide and pomalidomide in the therapy of multiple myeloma. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| United Kingdom | 1 | 25% |
| Switzerland | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 103 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 15% |
| Researcher | 12 | 12% |
| Student > Ph. D. Student | 10 | 10% |
| Student > Master | 9 | 9% |
| Other | 7 | 7% |
| Other | 15 | 14% |
| Unknown | 35 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 22% |
| Biochemistry, Genetics and Molecular Biology | 15 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 10% |
| Agricultural and Biological Sciences | 9 | 9% |
| Chemistry | 7 | 7% |
| Other | 8 | 8% |
| Unknown | 32 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2023.
All research outputs
#2,202,316
of 25,374,917 outputs
Outputs from Experimental Hematology & Oncology
#16
of 366 outputs
Outputs of similar age
#14,402
of 187,174 outputs
Outputs of similar age from Experimental Hematology & Oncology
#1
of 2 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 366 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,174 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them